ATE365039T1 - 4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl- carbonyl)piperidin derivate und verwandte verbindungen als histamin h3 antagonsiten zur behandlung von neurologischen erkrankungen wie alzheimer's - Google Patents
4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl- carbonyl)piperidin derivate und verwandte verbindungen als histamin h3 antagonsiten zur behandlung von neurologischen erkrankungen wie alzheimer'sInfo
- Publication number
- ATE365039T1 ATE365039T1 AT04726514T AT04726514T ATE365039T1 AT E365039 T1 ATE365039 T1 AT E365039T1 AT 04726514 T AT04726514 T AT 04726514T AT 04726514 T AT04726514 T AT 04726514T AT E365039 T1 ATE365039 T1 AT E365039T1
- Authority
- AT
- Austria
- Prior art keywords
- antagonites
- heterocyclylalkoxy
- histamine
- heterocyclyl
- alzheimer
- Prior art date
Links
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 title 2
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229960001340 histamine Drugs 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0308333.4A GB0308333D0 (en) | 2003-04-10 | 2003-04-10 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE365039T1 true ATE365039T1 (de) | 2007-07-15 |
Family
ID=9956580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04726514T ATE365039T1 (de) | 2003-04-10 | 2004-04-08 | 4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl- carbonyl)piperidin derivate und verwandte verbindungen als histamin h3 antagonsiten zur behandlung von neurologischen erkrankungen wie alzheimer's |
Country Status (22)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050256118A1 (en) * | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| EP1717235A3 (en) * | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
| KR101397913B1 (ko) | 2005-05-30 | 2014-05-26 | 엠에스디 가부시키가이샤 | 신규 피페리딘 유도체 |
| US7553964B2 (en) * | 2005-06-03 | 2009-06-30 | Abbott Laboratories | Cyclobutyl amine derivatives |
| ATE450526T1 (de) | 2005-06-20 | 2009-12-15 | Schering Corp | Als antagonisten von histamin h3 geeignete piperidinderivate |
| US7408066B2 (en) | 2005-06-20 | 2008-08-05 | Schering Corproation | Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists |
| GB0514812D0 (en) * | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| CA2623025A1 (en) | 2005-09-20 | 2007-03-29 | Schering Corporation | 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist |
| US7943605B2 (en) | 2005-10-27 | 2011-05-17 | Ucb Pharma S.A. | Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses |
| TW200730498A (en) | 2005-12-20 | 2007-08-16 | Glaxo Group Ltd | Compounds |
| CA2634847A1 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Substituted aniline derivatives useful as histamine h3 antagonists |
| CA2634250A1 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists |
| BRPI0713836A2 (pt) | 2006-07-25 | 2013-05-28 | Cephalon Inc | composto, composiÇço farmacÊutica e mÉtodo para tratar distérbio |
| TW200823204A (en) * | 2006-10-17 | 2008-06-01 | Arena Pharm Inc | Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| AU2008208653B2 (en) * | 2007-01-22 | 2012-11-22 | Pfizer Products Inc. | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
| CA2693169C (en) | 2007-07-19 | 2016-01-12 | Metabolex, Inc. | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders |
| BRPI0914891A2 (pt) * | 2008-06-20 | 2015-11-24 | Metabolex Inc | agonistas de aril gpr119 e usos dos mesmos |
| JP5909185B2 (ja) | 2009-10-01 | 2016-04-26 | シマベイ セラピューティクス， インコーポレーテッド | 置換テトラゾール−１−イルフェノキシメチルチアゾール−２−イルピペリジニルピリミジン塩 |
| WO2011163090A1 (en) | 2010-06-23 | 2011-12-29 | Metabolex, Inc. | Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| BR112014013461A2 (pt) | 2011-12-08 | 2017-06-13 | Taisho Pharmaceutical Co Ltd | derivado de fenilpirrol |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| HUP1300139A2 (en) * | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
| EP2970196B1 (en) | 2013-03-15 | 2020-11-25 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| WO2016169421A1 (zh) | 2015-04-21 | 2016-10-27 | 江苏恒瑞医药股份有限公司 | 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用 |
| US10292983B2 (en) | 2016-08-03 | 2019-05-21 | Cymabay Therapeutics, Inc. | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
| TWI821537B (zh) * | 2019-03-05 | 2023-11-11 | 日商衛材R&D企管股份有限公司 | 五環式雜環化合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166853A (en) * | 1978-05-05 | 1979-09-04 | The Upjohn Company | Antihypertensive 7-trifluoromethyl-4-aminoquinolones |
| US5364791A (en) * | 1992-05-14 | 1994-11-15 | Elisabetta Vegeto | Progesterone receptor having C. terminal hormone binding domain truncations |
| DE69334150T2 (de) * | 1992-05-14 | 2008-03-13 | Baylor College Of Medicine, Houston | Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie |
| DE4407139A1 (de) * | 1994-03-04 | 1995-09-07 | Thomae Gmbh Dr K | Aryl-1-azacycloalkane und deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung |
| CA2214288C (en) * | 1996-09-18 | 2006-07-18 | Lonza Ag | Process for the preparation of 1-acyl-4-arylpiperidines |
| EP0837065A1 (de) * | 1996-10-16 | 1998-04-22 | Ciba SC Holding AG | Phenylglycidylether-HALS |
| BR0108088A (pt) * | 2000-07-13 | 2004-04-06 | Abbott Lab | Pirrolidinas 1,3-dissubstituìdas e 1,3,3-trissubstituìdas como ligandos receptores de histamina-3 e suas aplicações terapêuticas |
| US6515013B2 (en) * | 2000-07-13 | 2003-02-04 | Abbott Laboratories | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| BRPI0113162B8 (pt) * | 2000-08-08 | 2021-05-25 | Johnson & Johnson | compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos |
| PL210793B1 (pl) * | 2001-02-28 | 2012-03-30 | Merck & Co Inc | Acylowane pochodne piperydyny |
| AU2002306848A1 (en) * | 2001-03-23 | 2002-10-08 | Elan Pharmaceuticals, Inc. | Methods of treating alzheimer's disease with piperidin derivates |
| US7459461B2 (en) * | 2001-10-19 | 2008-12-02 | Ortho-Mcneil Pharmaceutical, Inc. | Phosphonic acid compounds as inhibitors of serine proteases |
-
2003
- 2003-04-10 GB GBGB0308333.4A patent/GB0308333D0/en not_active Ceased
-
2004
- 2004-04-07 AR ARP040101188A patent/AR044006A1/es not_active Application Discontinuation
- 2004-04-08 BR BRPI0409110-8A patent/BRPI0409110A/pt not_active Application Discontinuation
- 2004-04-08 CA CA002521899A patent/CA2521899A1/en not_active Abandoned
- 2004-04-08 US US10/551,985 patent/US20060205774A1/en not_active Abandoned
- 2004-04-08 AU AU2004228949A patent/AU2004228949B2/en not_active Ceased
- 2004-04-08 JP JP2006505136A patent/JP2006522771A/ja active Pending
- 2004-04-08 TW TW093109666A patent/TW200503710A/zh unknown
- 2004-04-08 ES ES04726514T patent/ES2288681T3/es not_active Expired - Lifetime
- 2004-04-08 MX MXPA05010816A patent/MXPA05010816A/es not_active Application Discontinuation
- 2004-04-08 KR KR1020057019137A patent/KR20050111638A/ko not_active Withdrawn
- 2004-04-08 WO PCT/EP2004/003985 patent/WO2004089373A1/en not_active Ceased
- 2004-04-08 DE DE602004007119T patent/DE602004007119T2/de not_active Expired - Fee Related
- 2004-04-08 RU RU2005134006/04A patent/RU2005134006A/ru not_active Application Discontinuation
- 2004-04-08 AT AT04726514T patent/ATE365039T1/de not_active IP Right Cessation
- 2004-04-08 CN CNA2004800161953A patent/CN1805747A/zh active Pending
- 2004-04-08 EP EP04726514A patent/EP1610786B9/en not_active Expired - Lifetime
-
2005
- 2005-09-27 ZA ZA200507795A patent/ZA200507795B/en unknown
- 2005-10-06 CO CO05101708A patent/CO5640135A2/es not_active Application Discontinuation
- 2005-10-11 MA MA28548A patent/MA27726A1/fr unknown
- 2005-11-08 IS IS8118A patent/IS8118A/is unknown
- 2005-11-09 NO NO20055256A patent/NO20055256L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20060205774A1 (en) | 2006-09-14 |
| WO2004089373A1 (en) | 2004-10-21 |
| DE602004007119D1 (de) | 2007-08-02 |
| MA27726A1 (fr) | 2006-01-02 |
| CA2521899A1 (en) | 2004-10-21 |
| ZA200507795B (en) | 2006-07-26 |
| EP1610786A1 (en) | 2006-01-04 |
| NO20055256D0 (no) | 2005-11-09 |
| KR20050111638A (ko) | 2005-11-25 |
| RU2005134006A (ru) | 2006-04-10 |
| DE602004007119T2 (de) | 2008-02-21 |
| GB0308333D0 (en) | 2003-05-14 |
| AU2004228949B2 (en) | 2006-11-02 |
| TW200503710A (en) | 2005-02-01 |
| AU2004228949A1 (en) | 2004-10-21 |
| ES2288681T3 (es) | 2008-01-16 |
| AR044006A1 (es) | 2005-08-24 |
| NO20055256L (no) | 2006-01-10 |
| CO5640135A2 (es) | 2006-05-31 |
| EP1610786B1 (en) | 2007-06-20 |
| CN1805747A (zh) | 2006-07-19 |
| IS8118A (is) | 2005-11-08 |
| JP2006522771A (ja) | 2006-10-05 |
| EP1610786B9 (en) | 2008-02-27 |
| MXPA05010816A (es) | 2005-12-05 |
| BRPI0409110A (pt) | 2006-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE365039T1 (de) | 4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl- carbonyl)piperidin derivate und verwandte verbindungen als histamin h3 antagonsiten zur behandlung von neurologischen erkrankungen wie alzheimer's | |
| ATE466581T1 (de) | Verbindungen auf pyrimidin-basis als gsk-3-hemmer | |
| ATE504565T1 (de) | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen | |
| ATE410161T1 (de) | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen | |
| NO20064726L (no) | Imidazolforbindelser for behandling av neurodegenerative forstyrrelser | |
| DE60333371D1 (de) | 3-(sulfonamidoethyl)-indol-derivate zur verwendung als glucocorticoid-mimetika bei der behandlung von entzündlichen, allergischen und proliferativen erkrankungen | |
| DE60330895D1 (de) | Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen | |
| DE60231257D1 (de) | 1-(4-piperidinyl)-1,3-dihydro-2h-indol-2-on derivate und verwandte verbindungen als nociceptin analoge und orl1 liganden zur behandlung von schmerz | |
| DE602005022113D1 (de) | Phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
| ATE457989T1 (de) | Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit | |
| NO20063787L (no) | Terapeutiske preparater | |
| BR0308243A (pt) | Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero | |
| ATE361067T1 (de) | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen | |
| ATE506951T1 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit | |
| ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| ATE328879T1 (de) | Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv | |
| DE602004020685D1 (de) | Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3-cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i-epsilon | |
| ATE504580T1 (de) | Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit | |
| DE602004006118D1 (de) | 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER | |
| EP2077719A4 (en) | PIPERIDINE AND PYRROLIDIN BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE | |
| DE602005010744D1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas | |
| BRPI0412438A (pt) | novas amidas aza-heterocìclicas úteis para o tratamento da dor | |
| ATE523199T1 (de) | Pyridazinverbindungen und verfahren | |
| ATE348611T1 (de) | Derivate des phenoxy-n-'4-(isothiazolidin-1,1- dioxid-2yl)pheny)-valerian-säureamids und andere verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen und tumoren | |
| DE602004003829D1 (de) | 2-ä4-(phenylamino)-piperidin-1-ylü-n-phenyl-acetamid derivate und verwandte verbindungen als neuropeptid y5 (npy5) liganden zur behandlung von fettleibigkeit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |